This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Goldberg, L. R. Articles by Jessup, M. Search for Related Content PubMed Articles by Goldberg, L. R. Articles by Jessup, M. Related Collections Other heart failure Congestive Myocardial cardiomyopathy disease Epidemiology

(Circulation. 2006;113:2851-2860.)
© 2006 American Heart Association, Inc.

Contemporary Reviews in Cardiovascular Medicine

Stage B Heart Failure

Management of Asymptomatic Left Ventricular Systolic Dysfunction

Lee R. Goldberg, MD, MPH; Mariell Jessup, MD

From the University of Pennsylvania School of Medicine, Philadelphia, Pa.

Reprint requests to Lee Goldberg, MD, MPH, Heart Failure/Transplant Program, 6 Penn Tower, Hospital of the University of Pennsylvania, 3400 Spruce St, Philadelphia, PA 19104. E-mail lee.goldberg@uphs.upenn.edu

Key Words: heart failure • diagnosis • risk factors

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
Heart failure (HF) is a clinical syndrome characterized by symptoms of effort intolerance (eg, dyspnea and fatigue) and/or signs of fluid retention (eg, pulmonary congestion and peripheral edema) due to a variety of pathological processes that perturb normal cardiac function. Approximately 50% of HF patients present with evidence of left ventricular systolic dysfunction (LVSD) manifested as a low left ventricular ejection fraction (LVEF); the remaining half are found to have preserved left ventricular (LV) function.¹ HF with either low or normal LVEF represents a significant contemporary medical problem that affects an estimated 5 million people in the United States, with an annual mortality rate approaching 20%.²

HF is considered a progressive disorder that can be represented as a clinical continuum. The American College of Cardiology/American Heart Association (ACC/AHA) updated 2005 guidelines for the management of chronic HF identify 4 stages in this continuum (Figure 1)³ and link the stages in the natural history of HF to therapeutic recommendations for each stage. Previously, the New York Heart Association (NYHA) functional classification, based solely on the severity of symptoms (primarily of patients in ACC/AHA stage C or D), was used as a criteria to initiate or change HF therapy. NYHA classification can change over a relatively short period of time even in the absence of medication changes. Nearly every patient who presents to an emergency department for care has at least NYHA class III or IV symptoms; however, at discharge after treatment, many patients are minimally symptomatic. Clinicians must then . . . [Full Text of this Article]

This article has been cited by other articles:

				F. L. Dini, G. M. Rosa, P. Fontanive, V. Santonato, A. M. Napoli, M. Ciuti, and V. Di Bello Combining blood flow and tissue Doppler imaging with N-terminal pro-type B natriuretic peptide for risk stratification of clinically stable patients with systolic heart failure Eur J Echocardiogr, January 4, 2010; (2010) jep207v1. [Abstract] [Full Text] [PDF]

				A. Macabasco-O'Connell, S. Meymandi, and R. Bryg B-type Natriuretic Peptide (BNP) Is Useful in Detecting Asymptomatic Left Ventricular Dysfunction in Low-Income, Uninsured Patients Biol Res Nurs, January 1, 2010; 11(3): 280 - 287. [Abstract] [PDF]

				M. Klapholz {beta}-Blocker Use for the Stages of Heart Failure Mayo Clin. Proc., August 1, 2009; 84(8): 718 - 729. [Abstract] [Full Text] [PDF]

				K. Bibbins-Domingo, M. J. Pletcher, F. Lin, E. Vittinghoff, J. M. Gardin, A. Arynchyn, C. E. Lewis, O. D. Williams, and S. B. Hulley Racial Differences in Incident Heart Failure among Young Adults N. Engl. J. Med., March 19, 2009; 360(12): 1179 - 1190. [Abstract] [Full Text] [PDF]

				D. D. Schocken, E. J. Benjamin, G. C. Fonarow, H. M. Krumholz, D. Levy, G. A. Mensah, J. Narula, E. S. Shor, J. B. Young, and Y. Hong Prevention of Heart Failure: A Scientific Statement From the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group Circulation, May 13, 2008; 117(19): 2544 - 2565. [Abstract] [Full Text] [PDF]

				N. M. Albert and C. Lewis Recognizing and Managing Asymptomatic Left Ventricular Dysfunction: After Myocardial Infarction Crit. Care Nurse, April 1, 2008; 28(2): 20 - 37. [Full Text] [PDF]

				L. C. Costello-Boerrigter, G. Boerrigter, G. J. Harty, A. Cataliotti, M. M. Redfield, and J. C. Burnett Jr Mineralocorticoid Escape by the Kidney But Not the Heart in Experimental Asymptomatic Left Ventricular Dysfunction Hypertension, September 1, 2007; 50(3): 481 - 488. [Abstract] [Full Text] [PDF]

				W.H. Wilson Tang, G. S. Francis, D. A. Morrow, L. K. Newby, C. P. Cannon, R. L. Jesse, A. B. Storrow, R. H. Christenson, COMMITTEE MEMBERS, R. H. Christenson, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure Circulation, July 31, 2007; 116(5): e99 - e109. [Full Text] [PDF]